(2018). Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK. Osteoporos Int. http://doi.org/10.1007/s00198-017-4308-5.
(2018). Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on "real-world" data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. Clin Epidemiol. http://doi.org/10.2147/clep.s164112.
(2020). Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis. J Bone Miner Res. http://doi.org/10.1002/jbmr.4235.
(2020). Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (grade 3B-5D) chronic kidney disease: a population-based cohort study. J Bone Miner Res. http://doi.org/10.1002/jbmr.3961.
(2020). Higher prevalence of non-skeletal comorbidity related to X-linked hypophosphataemia: a UK parallel cohort study using CPRD. Rheumatology (Oxford). http://doi.org/10.1093/rheumatology/keaa859.
(2021). Predicting Imminent Fractures in Patients With a Recent Fracture or Starting Oral Bisphosphonate Therapy: Development and International Validation of Prognostic Models. J Bone Miner Res. http://doi.org/10.1002/jbmr.4414.
(2021). Bariatric surgery increases the rate of major fracture: self controlled case series study in UK Clinical Practice Research Datalink. J Bone Miner Res. http://doi.org/10.1002/jbmr.4405.
(2021). Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study. Health Technol Assess. http://doi.org/10.3310/hta25170.